Omeros Corporation

9.01
-0.18 (-1.96%)
At close: Feb 06, 2025, 2:23 PM
undefined%
Bid 8.98
Market Cap 521.84M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -3.14
PE Ratio (ttm) -2.87
Forward PE n/a
Analyst Hold
Ask 9.03
Volume 82,774
Avg. Volume (20D) 1,122,955
Open 9.26
Previous Close 9.19
Day's Range 8.97 - 9.29
52-Week Range 2.61 - 13.60
Beta undefined

About OMER

Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell tr...

Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2009
Employees 198
Stock Exchange NASDAQ
Ticker Symbol OMER

Analyst Forecast

According to 4 analyst ratings, the average rating for OMER stock is "Hold." The 12-month stock price forecast is $22.5, which is an increase of 149.86% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts
1 month ago
+37.27%
Omeros shares are trading higher after the company... Unlock content with Pro Subscription
2 months ago
+65.87%
Omeros shares are trading higher after the company reported better-than-expected Q3 EPS results. Also, Rodman & Renshaw initiated coverage on the stock with a Buy rating and announced a $9 price target.